Table 1.
Characteristics of patients who switched from originator adalimumab to biosimilar GP2017 or SB5, overall and stratified by diagnosis.
| Clinical characteristics | All patients (n = 1316) | GP2017 (n = 621) | SB5 (n = 695) | |||||
|---|---|---|---|---|---|---|---|---|
| GP2017 | SB5 | PsA | RA | AxSpA | PsA | RA | AxSpA | |
| Number of patients (N) | 621 | 695 | 146 | 213 | 262 | 173 | 253 | 269 |
| Age a , years (median, IQR) | 55 (44–64) | 56 (47–65) | 55 (47–62) | 63 (56–70) | 46 (39–57) | 55 (48–63) | 64 (57–71) | 49 (42–57) |
| Female, n (%) | 320 (52) | 328 (47) | 80 (55) | 158 (74) | 82 (31) | 58 (34) | 181 (72) | 89 (33) |
| Disease duration a , years (median, IQR) | 14 (9–20) | 14 (9–21) | 13 (9–17) | 17 (12–23) | 12 (8–18) | 14 (9–20) | 16 (11–24) | 12 (8–18) |
| Concomitant methotrexate a , n (%) | 337 (54) | 377 (54) | 87 (60) | 178 (84) | 73 (28) | 109 (63) | 213 (84) | 55 (20) |
| Duration of original bio-treatment before the switch (n, %) | ||||||||
| 1 year | 25 (4) | 42 (6) | 7 (5) | 4 (2) | 14 (5) | 13 (8) | 7 (3) | 22 (8) |
| 2–3 years | 76 (12) | 43 (6) | 20 (14) | 24 (11) | 32 (12) | 7 (4) | 9 (4) | 27 (10) |
| 4–5 years | 73 (12) | 53 (8) | 16 (11) | 31 (15) | 26 (10) | 16 (9) | 18 (7) | 19 (7) |
| 6+ years | 447 (72) | 557 (80) | 103 (71) | 154 (72) | 190 (73) | 137 (79) | 219 (86) | 201 (75) |
| Stopped biosimilar treatment within 180 days (n, %) | 33 (5) | 40 (6) | 10 (7) | 8 (4) | 15 (6) | 6 (4) | 18 (7) | 16 (6) |
Source: Reprinted from Nabi et al. 17 with permission.
a
At baseline.
AxSpA, axial spondyloarthritis; IQR, interquartile range; PsA, psoriatic arthritis; RA, rheumatoid arthritis.